Comerica Bank decreased its position in shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 4.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 86,176 shares of the company’s stock after selling 4,116 shares during the quarter. Comerica Bank’s holdings in Teva Pharmaceutical Industries were worth $699,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Northwestern Mutual Wealth Management Co. boosted its position in Teva Pharmaceutical Industries by 4.0% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 19,861 shares of the company’s stock valued at $311,000 after purchasing an additional 767 shares in the last quarter. ARK Investment Management LLC raised its stake in shares of Teva Pharmaceutical Industries by 3.6% in the first quarter. ARK Investment Management LLC now owns 24,462 shares of the company’s stock worth $384,000 after purchasing an additional 856 shares during the last quarter. HighPoint Advisor Group LLC raised its stake in shares of Teva Pharmaceutical Industries by 8.7% in the first quarter. HighPoint Advisor Group LLC now owns 12,920 shares of the company’s stock worth $188,000 after purchasing an additional 1,035 shares during the last quarter. American International Group Inc. raised its stake in shares of Teva Pharmaceutical Industries by 1.1% in the first quarter. American International Group Inc. now owns 107,121 shares of the company’s stock worth $1,680,000 after purchasing an additional 1,203 shares during the last quarter. Finally, Point View Wealth Management Inc. raised its stake in shares of Teva Pharmaceutical Industries by 1.7% in the second quarter. Point View Wealth Management Inc. now owns 74,798 shares of the company’s stock worth $690,000 after purchasing an additional 1,273 shares during the last quarter. 57.85% of the stock is currently owned by institutional investors and hedge funds.
Shares of TEVA traded down $0.24 during trading hours on Friday, hitting $7.94. The stock had a trading volume of 19,442,304 shares, compared to its average volume of 22,780,964. The company’s fifty day simple moving average is $7.21 and its 200 day simple moving average is $11.25. The company has a debt-to-equity ratio of 1.73, a quick ratio of 0.62 and a current ratio of 0.96. Teva Pharmaceutical Industries Ltd has a 12-month low of $6.07 and a 12-month high of $25.13. The firm has a market cap of $8.88 billion, a P/E ratio of 2.84, a P/E/G ratio of 0.85 and a beta of 1.68.
Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Wednesday, August 7th. The company reported $0.57 EPS for the quarter, beating the consensus estimate of $0.55 by $0.02. The company had revenue of $4.34 billion for the quarter, compared to analyst estimates of $4.25 billion. Teva Pharmaceutical Industries had a positive return on equity of 16.04% and a negative net margin of 21.94%. The firm’s revenue was down 7.7% compared to the same quarter last year. During the same period last year, the company posted $0.78 earnings per share. As a group, sell-side analysts predict that Teva Pharmaceutical Industries Ltd will post 2.25 earnings per share for the current fiscal year.
Several research analysts have recently issued reports on the company. CIBC upgraded Teva Pharmaceutical Industries from a “market perform” rating to an “outperform” rating and set a $12.00 price objective for the company in a research note on Monday, June 3rd. ValuEngine raised Teva Pharmaceutical Industries from a “sell” rating to a “hold” rating in a report on Tuesday. Citigroup set a $13.00 price objective on Teva Pharmaceutical Industries and gave the company a “buy” rating in a report on Monday, June 17th. Cowen set a $9.00 price objective on Teva Pharmaceutical Industries and gave the company a “hold” rating in a report on Wednesday, August 7th. Finally, Morgan Stanley lowered Teva Pharmaceutical Industries from an “equal weight” rating to an “underweight” rating and lowered their price target for the stock from $16.00 to $6.00 in a research note on Monday, July 15th. Six investment analysts have rated the stock with a sell rating, sixteen have issued a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $12.80.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.